Abstract: The present invention relates to a method for identifying a subject at risk of developing hypertensive end organ damage, such as and in particular heart failure, comprising: a) obtaining a biological sample of said subject; b) determining the level of at least one non-myocytal marker in said sample; c) comparing the level of said marker to a standard level; and d) determining whether the level of the marker is indicative of a risk for developing hypertensive end organ damage. The non-myocytical marker preferably is galectin-3 or thrombospondin-2.

Abstract: The invention relates to the fields of molecular biology and medicine, more specifically to treatment and prevention of heart disease. The invention provides alternative methods for counteracting, diminishing, treating, delaying and/or preventing heart disease.

Abstract: The invention is in the field of genomics and it provides an in vitro method for predicting whether a compound is genotoxic in vivo. It provides a method that employs the analysis of expression profiles of primary mouse hepatocytes as an in vitro system to discriminate false GTX compounds from true GTX carcinogens. It was found that differential expression of a number of genes could reliably predict whether a compound was a true genotoxic compound.

Abstract: The present invention relates to a method for identifying a subject at risk of developing heart failure, comprising: (a) determining the level of one or more biological markers in a biological sample of said subject; (b) comparing the level of said biological marker to a standard level of the same biological marker; and (C) determining whether the level of the marker is indicative of a risk for developing heart failure, wherein the biological marker is Krüppel Like Factor 15 (KLF-15) and/or lysosomal integral membrane protein-2 (LIMP-2) and/or fragments and/or variants thereof, and/or wherein the biological marker is a gene coding for KLF15 and/or LIMP-2, and/or fragments and/or variants thereof.

Abstract: The invention is in the field of molecular medicine. It provides antagonistic compounds for frizzled 1 and/or frizzled 2 receptors, which may be useful in molecular imaging of the wound healing process after myocardial infarction and in therapeutic intervention into wound healing after remodeling of the heart, thereby ameliorating the consequences of myocardial infarction. The invention provides a method for antagonizing frizzled-1 or frizzled-2 receptors, wherein the receptor is contacted with a composition comprising a linear fragment of Wnt3(a) or Wnt5a or a functional analogue thereof, which comprises at least one cysteine residue, one threonine residue, one aspartic acid residue and one glycine residue.

Abstract: Described herein are methods for identifying a subject at risk of progression of heart failure. In some embodiments, the level of galectin-3 in a biological sample from a human subject may be measured and compared to a standard level indicative of risk of progression of heart failure, wherein an elevated level of galectin-3 in the sample indicates a risk of progression of heart failure.

Abstract: The present invention relates to methods for the identification of genotoxic carcinogenic compounds. In particular, a method is disclosed for the identification of genotoxic carcinogenic compounds wherein a eukaryotic cell is exposed to a potentially genotoxic compound in a culture medium where after samples are taken from the cell and/or the culture medium at at least one predetermined time point which samples are then analysed for increased or decreased expression levels of at least three DNA repair genes as compared to a control cell that is not exposed to the carcinogenic compound.

Abstract: Crucial to designing anti-angiogenic and vascular targeting approaches is the identification of specific target molecules. We compared transcriptional profiles of tumor endothelial cells with that of normal resting endothelial cells, normal but angiogenically activated placental endothelial cells, and cultured endothelial cells. Although the majority of transcripts were classified as general angiogenesis markers, we identified 17 genes that show specific overexpression in tumor endothelium. Antibody targeting of four cell-surface expressed or secreted products (vimentin, CD59, HMGB1 and IGFBP7) inhibited angiogenesis in vitro and in vivo. Finally, targeting endothelial vimentin in a mouse tumor model significantly inhibited tumor growth and reduced microvessel density. Our results demonstrate the utility of the identification and subsequent targeting of specific tumor endothelial markers for anticancer therapy.

Abstract: The invention relates to a method for the classification of cancer using a specific multi-class tumor classifier comprising specific sets of genes for the interpretation of expression data obtained from tumor samples. More specifically, the method of the present invention provides an accurate, reproducible, robust, objective and easy to perform method for determining the primary site of a Cancer of Unknown Primary site (CUP). For this purpose, the method provides that a classifier parameter is determined by comparing an expression profile of a tumor sample with a template profile representative for a particular primary site of a cancer.

Abstract: The invention is in the field of weight management, in particular in the field of weight management by influencing the mechanisms of body-weight regulation. Intact pea protein and intact wheat protein were found to be effective in reducing appetite or inducing or increasing satiety when brought into contact with their receptors in the duodenum. Since it is known that intact proteins hydrolyse in the gastrointestinal tract, intact pea protein and intact wheat protein will not exhibit their satiating effect when ingested in a conventional oral preparation. Therefore, special care should be taken to deliver the intact proteins to the duodenum in order for them to arrive there intact. One object of the invention may therefore be achieved by incorporating the intact protein in an enteric delivery vehicle.

Abstract: The present invention relates to a method for identifying a subject at risk of developing hypertensive end organ damage, such as and in particular heart failure, comprising: a) obtaining a biological sample of said subject; b) determining the level of at least one non-myocytal marker in said sample; c) comparing the level of said marker to a standard level; and d) determining whether the level of the marker is indicative of a risk for developing hypertensive end organ damage. The non-myocytical marker preferably is galectin-3 or thrombospondin-2.

Abstract: A breath condensing apparatus includes a mouthpiece, a condenser having an inlet coupled to the mouthpiece, a first container for collecting condensate communicating with an outlet of the condenser, and a second container for collecting residual, non-condensed exhaled breath coupled to the condenser. A method of condensing exhaled breath includes the features of receiving exhaled vapor into a condenser, condensing at least part of the exhaled vapor, collecting at least part of residual, non-condensed exhaled vapor, recirculating at least part of the collected residual vapor through the condenser, condensing at least part of the recirculated vapor, and collecting condensate.

Abstract: The present invention relates to peptides that are able to interact with ruptured atherosclerotic plaque-associated antibodies, which peptides comprise an immunoreactive part of one of the amino acid sequences according to SEQ ID NOS: 1-25. The invention further relates to a diagnostic reagent comprising the peptides, to the use of the method and to a method and test kit for the diagnosis of a sample from an individual for the presence therein of antibodies that are indicative of the presence of ruptured atherosclerotic plaques in the individual.

Abstract: The invention is directed to embolic material comprising spherical, homogeneous and substantially non-porous radiopaque polymer particles based on at least one hydrophilic monomer and at least one radiopaque monomer according to general formula wherein R is H, methyl or ethyl, and R1 is I, Br or wherein R2 is O, NH, O—[CH2—CH2—O]p—C(O)—, O—[CH2]m—O—C(O)—, O—[CH2]p—, NH—[CH2—CH2—O]p—C(O)—, NH—[CH2]m—O—C(O)- or NH—[CH2]p— wherein m>1 and p?1, R3 is I or Br and n is 1, 2 or 3, the iodine and/or bromine content being at least 5 wt. % based on the dry weight of the particle, the said particles having an average particle diameter of at least 10 ?m and being able to imbibe water up to a volume increase of the particle of at least 10%.

Abstract: The invention is directed to an intrinsically radio-opaque two component bone cement, comprising a first component which contains at least one acrylate monomer and a second component which contains at least one initiator for the polymerisation of said acrylate monomer, wherein the at least one iodine containing radio-opacity providing polymer is present in at least one of the two components and wherein the cement, when mixed into a slurry has a viscosity, which is sufficiently low to allow injection of the cement slurry through a needle with a diameter in the range of 10-15 G used in percutaneous vertebroplasty.

Abstract: Methods of identifying specific target molecules for design of anti-angiogenic and vascular targeting approaches are disclosed. Transcriptional profiles of tumor endothelial cells were compared with that of normal resting endothelial cells, normal but angiogenically activated placental endothelial cells, and cultured endothelial cells. Although the majority of transcripts were classified as general angiogenesis markers, 17 genes were identified that show specific overexpression in tumor endothelium. Antibody targeting of four cell-surface expressed or secreted products (vimentin, CD59, HMGB1 and IGFBP7) inhibited angiogenesis in vitro and in vivo. Finally, targeting endothelial vimentin in a mouse tumor model significantly inhibited tumor growth and reduced microvessel density. The results demonstrate the utility of the identification and subsequent targeting of specific tumor endothelial markers for anticancer therapy.

Abstract: Method and arrangement for performing measurements of the topography of a surface (20), such as topography of an eye surface (20), wherein projecting means (1, 12) for projecting an image onto said surface (20) comprises a projection light source (1), and wherein at least a fraction of light leaving the surface (20) as a result of said projection is received using one or more receiving units (31, 32), such as charged coupled device (CCD) based cameras. The topography of the surface (20) is determined by analysis of said fraction of light leaving the surface (20), due to thermal emission and the image projected onto the surface (20) is projected with light comprising a colour for which the surface (20) is opaque, such as infrared light.

Abstract: The invention relates to a device for preparing specimens for a cryo-electron microscope, comprising an environmental chamber, a holder for a sample or a carrier, and at least one blotting element to which a medium for absorbing liquid is or can be attached, both disposed in the environmental chamber, and a cooling medium for cooling down said sample. The said blotting element can be moved towards the sample or carrier in a controlled manner.

Abstract: The present invention relates to a method for identifying a subject at risk of developing hypertensive end organ damage, such as and in particular heart failure, comprising: a) obtaining a biological sample of said subject; b) determining the level of at least one non-myocytal marker in said sample; c) comparing the level of said marker to a standard level; and d) determining whether the level of the marker is indicative of a risk for developing hypertensive end organ damage. The non-myocytical marker preferably is galectin-3 or thrombospondin-2.

Abstract: A device for determining a chemical composition of a living eye including a light emitting unit configured to emit a light beam, a light guidance unit including at least one first focusing lens having an entry surface and an exit surface to be brought in optical contact with the eye and to illuminate at least part of the eye with the light beam emitted by the light emitting unit and to receive and guide at least a fraction of a light beam leaving the eye towards the light detecting unit. The light guidance unit is arranged to illuminate the part of the eye with the light beam having an oblique angle of incidence with respect to a visual axis of the eye, and includes a second focusing lens having an entry surface and an exit surface. Further, the exit surface of the first focusing lens has a curvature conformal to a wave front of the light beam leaving the exit surface and impinging on the part of the eye.